Endocrinology, Vol 132, 1359-1366, Copyright © 1993 by Endocrine Society

ARTICLES

The effect of leukemia inhibitory factor on bone in vivo

J Cornish, K Callon, A King, S Edgar and IR Reid
Department of Medicine, University of Auckland, New Zealand.

The local effects of leukemia inhibitory factor (LIF) on bone turnover in vivo have been examined. Recombinant murine LIF (0.2 micrograms) or vehicle was injected daily for 5 days over the right hemicalvaria, and the mice were killed on day 6 or 13. Effects on calvarial bone morphology were assessed using quantitative histomorphometry of nondecalcified bone tissue. Increased bone resorption was present in LIF-treated hemicalvaria compared with that in the noninjected hemicalvaria or calvaria from mice injected with vehicle alone at both 6 and 13 days. Significant increases in LIF-treated animals were as follows. Eroded surface increased 10-fold (P = 0.022), osteoclast surface increased 5-fold (P = 0.003), osteoclast numbers increased 3- fold (P = 0.002), and the number of osteoclast nuclei increased 3-fold (P = 0.009). Fibrotic tissue was laid down in the resorption defects, and there was an accompanying thickening of the periosteum (3 times greater in LIF-injected animals; P = 0.003), causing the overall thickness of the treated bones to be almost doubled (P = 0.045). Indices of bone formation were increased in animals treated with LIF. Osteoblast numbers, osteoblast surface, and osteoid area were doubled (P = 0.012, 0.016, and 0.058, respectively). Similar effects of LIF were seen in indomethacin-treated animals. Small but statistically significant morphological changes were also seen in the left noninjected hemicalvariae when LIF-treated animals were compared to controls. LIF increased periosteal area (P = 0.01) and total mineralized bone area (P = 0.002). In conclusion, LIF accelerated bone turnover locally in a prostaglandin-independent manner in normal mice, demonstrating its potential to modify in vivo bone cell function dramatically.

This article has been cited by other articles:

				J. Lorenzo, M. Horowitz, and Y. Choi Osteoimmunology: Interactions of the Bone and Immune System Endocr. Rev., June 1, 2008; 29(4): 403 - 440. [Abstract] [Full Text] [PDF]

				J. E. Aubin, R. Bouillon, T. A. Guise, and I. R. Reid Meeting Report from the 17th Scientific Meeting of the International Bone and Mineral Society: June 24-29, 2007 in Montreal, Quebec, Canada IBMS BoneKEy, November 1, 2007; 4(11): 299 - 313. [Full Text] [PDF]

				J. Cornish, K. E. Callon, D. Naot, K. P. Palmano, T. Banovic, U. Bava, M. Watson, J.-M. Lin, P. C. Tong, Q. Chen, et al. Lactoferrin Is a Potent Regulator of Bone Cell Activity and Increases Bone Formation in Vivo Endocrinology, September 1, 2004; 145(9): 4366 - 4374. [Abstract] [Full Text] [PDF]

				R. A. Abbud, R. Kelleher, and S. Melmed Cell-Specific Pituitary Gene Expression Profiles after Treatment with Leukemia Inhibitory Factor Reveal Novel Modulators for Proopiomelanocortin Expression Endocrinology, February 1, 2004; 145(2): 867 - 880. [Abstract] [Full Text] [PDF]

				P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-{kappa}B Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvariae J. Immunol., September 15, 2002; 169(6): 3353 - 3362. [Abstract] [Full Text] [PDF]

				M. H. Mitchell, R. J. Swanson, and S. Oehninger In Vivo Effect of Leukemia Inhibitory Factor (LIF) and an Anti-LIF Polyclonal Antibody on Murine Embryo and Fetal Development Following Exposure at the Time of Transcervical Blastocyst Transfer Biol Reprod, August 1, 2002; 67(2): 460 - 464. [Abstract] [Full Text] [PDF]

				C. J. Auernhammer and S. Melmed Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function Endocr. Rev., June 1, 2000; 21(3): 313 - 345. [Abstract] [Full Text]

				R. A. Gadient and P. H. Patterson Leukemia Inhibitory Factor, Interleukin 6, and Other Cytokines Using the GP130 Transducing Receptor: Roles in Inflammation and Injury Stem Cells, May 1, 1999; 17(3): 127 - 137. [Abstract] [Full Text]

				J. Cornish, K. E. Callon, D. H. Coy, N.-Y. Jiang, L. Xiao, G. J. S. Cooper, and I. R. Reid Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo Am J Physiol Endocrinol Metab, December 1, 1997; 273(6): E1113 - E1120. [Abstract] [Full Text] [PDF]

				J. Cornish, K. E. Callon, G. C. Nicholson, and I. R. Reid Parathyroid Hormone-Related Protein-(107-139) Inhibits Bone Resorption in Vivo Endocrinology, March 1, 1997; 138(3): 1299 - 1304. [Abstract] [Full Text] [PDF]

				A. N. Economides, J. V. Ravetch, G. D. Yancopoulos, and N. Stahl Designer Cytokines: Targeting Actions to Cells of Choice Science, November 24, 1995; 270(5240): 1351 - 1353. [Abstract] [PDF]

				M. H. Mitchell, R. J. Swanson, G. D. Hodgen, and S. Oehninger Enhancement of In Vitro Murine Embryo Development by Recombinant Leukemia Inhibitory Factor Reproductive Sciences, July 1, 1994; 1(3): 215 - 219. [Abstract] [PDF]